1,165 results match your criteria: "Immune Thrombocytopenia and Pregnancy"

Immune thrombocytopenia (ITP) is a common hematological disorder. Our previous study has found that exosomal miR-146a-5p derived from bone marrow mesenchymal stromal cells (BMSCs) regulate Th17/Treg balance to alleviate ITP. This work further investigated the role of miR-146a-5p in ITP with pregnancy.

View Article and Find Full Text PDF

Thrombocytopenia during pregnancy is often thought to be associated with severe bleeding manifestations. Three are the main disorders associated with this condition: gestational thrombocytopenia (GT), immune thrombocytopenia (ITP), and inherited thrombocytopenias (ITs). Reaching the correct diagnosis of this condition has relevant therapeutic and outcome implications.

View Article and Find Full Text PDF

ITP in pregnancy: diagnostics and therapeutics in 2024.

Hematology Am Soc Hematol Educ Program

December 2024

Division of Hematology, Massachusetts General Hospital, Boston, MA.

Thrombocytopenia will occur in 10% of pregnancies-ranging from the clinically benign to processes that can threaten both mother and fetus. Accurately identifying the specific etiology and appropriate clinical management is challenging due to the breadth of possible diagnoses and the potential of shared features among them. Further complicating diagnostic certainty is the lack of confirmatory testing for most possible pathophysiologies.

View Article and Find Full Text PDF

Antigen-specific immunotherapy for platelet alloimmune disorders.

Hum Immunol

November 2024

Versiti Blood Research Institute, Milwaukee, WI, United States; Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI, United States. Electronic address:

Article Synopsis
View Article and Find Full Text PDF

Objectives: To evaluate the effect of idiopathic thrombocytopenic purpura (ITP) on pregnancies and the role of the delta hemoglobin indices in the evaluation of treatment effectiveness.

Methods: This case-control study was conducted with 23 ITP and 115 low-risk pregnancies. Obstetric outcomes (fetal growth retardation (FGR), preterm delivery) and neonatal outcomes (weights, APGAR scores, NICU admissions, thrombocytopenia) were recorded.

View Article and Find Full Text PDF

When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?

Br J Haematol

December 2024

Internal Medicine Department, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.

Article Synopsis
  • Intravenous immunoglobulin (IVIg) is a preferred treatment for severe immune thrombocytopaenia (ITP), but its high cost and limited availability led to specific French guidelines on its use.
  • A study assessed IVIg prescribing practices in real-life situations, evaluating compliance with these French guidelines in a sample of 114 hospitalized patients from 2016 to 2020.
  • Findings showed that 84.4% of IVIg prescriptions were compliant with guidelines, and the use was notably more frequent among younger patients, with factors like corticosteroid resistance and need for surgical preparation influencing non-compliance.
View Article and Find Full Text PDF
Article Synopsis
  • Primary immune thrombocytopenia (ITP) is an autoimmune disorder causing low platelet counts due to the immune system attacking platelets, complicating management during pregnancy.
  • The review discusses the pathophysiology, diagnostic methods, and personalized management strategies for ITP in pregnant women, emphasizing a multidisciplinary approach and individual treatment plans.
  • Current treatments include corticosteroids and IVIG as first-line therapy, with emerging research suggesting new therapies, though more studies are needed to ensure their safety and effectiveness for both mother and fetus.
View Article and Find Full Text PDF
Article Synopsis
  • A 25-year-old woman with immune thrombocytopenic purpura (ITP) presented with a spontaneous petechial rash, abdominal pain, and dizziness, indicating severe thrombocytopenia.
  • Imaging revealed free fluid in the peritoneal cavity and a ruptured ovarian cyst, leading to significant internal bleeding.
  • The patient was treated conservatively with platelet transfusions, steroids, and romiplostim to manage her severe bleeding and ITP relapse.
View Article and Find Full Text PDF
Article Synopsis
  • Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare condition where a mother’s immune system attacks her fetus's platelets, primarily due to antibodies against the HPA-1a antigen; current prevention and treatment options are lacking.
  • A study tested the efficacy of RLYB212, a monoclonal antibody that targets HPA-1a, to see if it could eliminate HPA-1a-positive platelets after a simulated fetal-maternal hemorrhage; subjects received either RLYB212 or a placebo in a blind trial.
  • Results showed that RLYB212 significantly reduced HPA-1a-positive platelets and was well tolerated, indicating its promise as a potential
View Article and Find Full Text PDF

Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management.

Expert Rev Hematol

September 2024

NewYork-Presbyterian Hospital/Weill Cornell Medicine, Department of Pediatrics and Department of Medicine, Division of Hematology and Medical Oncology, New York, NY, USA.

Article Synopsis
  • Immune thrombocytopenia (ITP) during pregnancy poses diagnostic and treatment difficulties, and current strategies for managing it are explored, including the impact on pregnancy outcomes.
  • The review examines how ITP affects both pregnancy and women with chronic ITP, as well as the effectiveness of first-line treatments and challenges associated with more resistant cases.
  • There's emerging interest in using thrombopoietin receptor agonists like romiplostim for severe cases, highlighting its potential risks, such as venous thromboembolism, and the importance of appropriate diagnostic and treatment approaches for both mothers and newborns.
View Article and Find Full Text PDF
Article Synopsis
  • The study compared maternal and neonatal outcomes in 62 pregnant women diagnosed with idiopathic thrombocytopenic purpura (ITP) based on different platelet counts.
  • It found that most patients had ITP diagnosed during pregnancy, with an average maternal platelet count during birth of 84/μL and an average neonatal platelet count of 242/μL.
  • Results showed no significant differences in morbidity and mortality rates for mothers and newborns, attributed to effective collaboration among medical departments involved in their care.
View Article and Find Full Text PDF

Rituximab as a treatment for refractory immune thrombocytopenia during pregnancy.

Blood Coagul Fibrinolysis

July 2024

Serviço de Obstetrícia, Departamento da Mulher e da Medicina Reprodutiva, Centro Materno-Infantil do Norte, Unidade Local de Saúde de Santo António, Porto, Portugal.

Article Synopsis
View Article and Find Full Text PDF
Article Synopsis
  • The study investigated neonatal outcomes in 55 pregnant women with immune thrombocytopenic purpura (ITP), finding that 30.9% of their babies had neonatal thrombocytopenia, often mild bleeding.
  • A significant link was identified between maternal splenectomy and lower neonatal platelet counts (<100 x 10^9/L), but overall, no strong correlations between maternal and neonatal platelet counts were found.
  • The results suggest that while there is an increased risk of neonatal thrombocytopenia in infants of mothers with ITP, predicting individual cases remains challenging, highlighting the need for close monitoring after birth.
View Article and Find Full Text PDF